Clonal expansion in aged normal tissues has been implicated in the development of cancer. However, the chronology and risk dependence of the expansion are poorly understood. Here we intensively sequence 682 micro-scale oesophageal samples and show, in physiologically normal oesophageal epithelia, the progressive age-related expansion of clones that carry mutations in driver genes (predominantly NOTCH1), which is substantially accelerated by alcohol consumption and by smoking. Driver-mutated clones emerge multifocally from early childhood and increase their number and size with ageing, and ultimately replace almost the entire oesophageal epithelium in the extremely elderly. Compared with mutations in oesophageal cancer, there is a marked overrepresentation of NOTCH1 and PPM1D mutations in physiologically normal oesophageal epithelia; these mutations can be acquired before late adolescence (as early as early infancy) and significantly increase in number with heavy smoking and drinking. The remodelling of the oesophageal epithelium by driver-mutated clones is an inevitable consequence of normal ageing, which-depending on lifestyle risks-may affect cancer development.
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Clonal expansion in aged normal tissues has been implicated in the development of cancer. However, the chronology and risk dependence of the expansion are poorly understood. Here we intensively sequence 682 micro-scale oesophageal samples and show, in physiologically normal oesophageal epithelia, the progressive age-related expansion of clones that carry mutations in driver genes (predominantly NOTCH1), which is substantially accelerated by alcohol consumption and by smoking. Driver-mutated clones emerge multifocally from early childhood and increase their number and size with ageing, and ultimately replace almost the entire oesophageal epithelium in the extremely elderly. Compared with mutations in oesophageal cancer, there is a marked overrepresentation of NOTCH1 and PPM1D mutations in physiologically normal oesophageal epithelia; these mutations can be acquired before late adolescence (as early as early infancy) and significantly increase in number with heavy smoking and drinking. The remodelling of the oesophageal epithelium by driver-mutated clones is an inevitable consequence of normal ageing, which-depending on lifestyle risks-may affect cancer development.
Cancer is thought to comprise a heterogeneous population of neoplastic cells that show a complex hierarchical structure in terms of gene mutations [1] [2] [3] . According to recent studies [4] [5] [6] , the entire cancer hierarchy itself might be further embedded in higher-level hierarchies that are recursively generated by multiple rounds of positive selections, in which the acquisition of driver mutations has a central role 7 . Thus, before a cancer develops, many independent precancerous populations of clones are presumed to be present within apparently or physiologically normal tissues 8 . However, how these clones evolve from early infancy to the end of the lifespan, in terms of their frequency and size, and how their dynamics are affected by environmental and/or genetic factors to contribute to cancer is poorly understood. Major challenges to clarify these issues include rarity of such events, small size of clones and-more importantly-the difficulty of retrospectively analysing earlier clones that gave rise to cancer.
Oesophageal squamous cell carcinoma (ESCC) represents the most common oesophageal cancer among Asian populations 9 , in which the role of heavy alcohol drinking and smoking have long been demonstrated 10, 11 ; individuals with these lifestyle factors-which are hereafter referred to as 'lifestyle ESCC risks'-have a substantially increased risk of developing ESCC, with a hazard ratio of as high as 6.12 12 , and often develop multiple cancers or a second (metachronous) cancer after treatment of the primary tumour 13 . Moreover, in these high-risk individuals, TP53-mutated cells have been documented in physiologically normal oesophageal epithelia (PNE) 13, 14 , which suggests the presence of many precancerous foci before or at the onset of a cancer (known as 'field effects' 15 ). In this study, we investigated early clonal events in the oesophagus using multiple collections of micro-scale PNE samples (as small as 0.2 mm 2 in size) from individuals of various ages and varying lifestyle ESCC risk, followed by an unbiased detection of somatic mutations and copy-number abnormalities (CNAs), using whole-exome sequencing (WES).
Somatic mutations in PNE tissues
To assess clonal expansion within PNE, we first performed WES of DNA from 5-mm 2 PNE samples (n = 25) as well as cancer tissues (n = 2), collected from a surgically resected oesophagus (Extended Data Figs. 1, 2a) . Somatic mutations were detected in most PNE samples (24 out of 25) (Extended Data Fig. 2b-d) . In contrast to the abundant mutations shared between cancer samples, none of the mutations were shared among PNE samples that were mutually separated by 10-15 mm; small numbers of shared mutations were observed among closely positioned PNE samples (those separated by 1.5 mm) (Extended Data Fig. 2c, d ). These results suggest that pervasive expansions of multiple independent clones are present within the ESCC-bearing oesophagus.
To confirm the finding in this example and to extend the observation to the oesophagus in healthy individuals, we collected by punch biopsy Article reSeArcH a total of 157 PNE samples of various sizes (0.2 mm 2 (n = 53), 0.8 mm 2 (n = 31) or 4 mm 2 (n = 73)) from 130 specimens that were endoscopically obtained from patients with ESCC or dysplasia (n = 21) or healthy individuals (n = 40) with or without lifestyle ESCC risks (Extended Data Figs. 1a, 2e-g). Samples were also collected from cancer (n = 20) and dysplastic (n = 12) tissues. Multi-regional sampling was performed in 16 individuals with a median of 5 (range, 2−8) samples per case. WES detected a total of 7,930 somatic mutations in 182 out of 189 samples (Extended Data Fig. 3a) . The true-positive rate in 622 randomly selected variants from 105 samples was 95.7% (Methods). Mutations were detected in all PNE and cancer samples from patients with ESCC, the majority of whom had a long history of heavy drinking and smoking. Moreover, mutations were also detected in most samples from healthy individuals (99 out of 106). None of the mutations were shared across different PNE samples from multi-regional biopsies, except for two cases (UPN49 and UPN80) in which the samples were in a mutually close position (Extended Data Fig. 3b-j) . The number of detected mutations was affected by sample size. However, when sample size was stratified, mutation number linearly increased with the age of the subject, which was significantly accelerated by the presence of lifestyle ESCC risks (Fig. 1a) . The mutant-cell fraction (MCF) of the largest clone within a sample (maximum MCF) also increased with the subject's age, but was not significantly affected by lifestyle ESCC risk (Fig. 1b) .
Signatures of mutations were analysed to decipher the underlying mechanism of mutational processes. Combining mutational datasets from 5 published studies [16] [17] [18] [19] [20] , we analysed a total of 54,121 single nucleotide variants (SNVs) in 157 PNE, 12 dysplasia and 519 ESCC samples and identified 4 mutational signatures (designated as signatures A−D) that are predominant in ESCC and PNE ( Fig. 1c and Extended Data Fig. 4a ). Signature A was dominated by C>G/T changes at the TpCpA or TpCpT context, and conforms to COSMIC signatures 2 and 13, which have the unique features of mutations related to APOBEC cytidine deaminase activity 21 . Signature A was highly enriched in mutations in cancer-tissue samples, as compared with samples from PNE and dysplastic tissues (Fig. 1d) . Although not remarkable in PNE samples as a whole, signature A was more prominent in samples from individuals with a history of heavy smoking or drinking (high-risk individuals) than from individuals with no history of heavy smoking or drinking (low-risk individuals) (Extended Data Fig. 4b, c) .
Corresponding to the age-related 'Catalogue of somatic mutations in cancer' (COSMIC) signature 1, signature B was seen across all samples and represented the major source of mutations in cancer-tissue samples and PNE samples from low-risk individuals ( Fig. 1d and Extended Data Fig. 4a ). Signature D is highly enriched in dysplastic tissues and PNE samples from high-risk individuals (Fig. 1d) ; it is mainly composed of T > C transitions at ApTpN sites with a conspicuous transcriptional strand bias (Fig. 1c) , and conformed to COSMIC signature 16 (signature 16) 21 . Accentuated in liver cancers from Japanese men 22 , signature 16 has recently been related to alcohol consumption among Asian patients with ESCC 18 , on the basis of its association with alcohol drinking and two risk alleles for ESCC that are involved in alcohol metabolism (ALDH2 (rs671) (A) and ADH1B (rs1229984) (G)). The association with the ALDH2 risk allele was also confirmed in oesophagus, hepatic and stomach cancers from the The Cancer Genome Atlas (TCGA) (Extended Data Fig. 4d ). Although resembling COSMIC signature 4, signature C was not significantly associated with smoking in ESCC samples (Extended Data Fig. 4e) , and the origin of this unique signature in oesophageal epithelium therefore remains to be elucidated.
Mutations in single cells in PNE
To obtain more insight into the mutations in PNE, we performed whole-genome sequencing of 13 colonies derived from single PNE cells, isolated from 7 individuals (Extended Data Fig. 1b) . In total, we detected 26,901 somatic variants, which were largely explained by signatures A-D (Fig. 2a, b and Extended Data Fig. 5 ). One or more driver mutations were detected in seven colonies. The mutation number in colonies from low-risk individuals linearly increased with age with an annual increase of 41.5 mutations per genome per year (R 2 = 0.926) or 0.53 mutations per exome per year (R 2 = 0.840) (Fig. 2c, d ), which is comparable to rates reported in intestinal mucosa and hepatic cells 23 . The accumulation of mutations for the entire genome was accelerated by lifestyle ESCC risk (51.9 mutations per genome per year), which was more prominent for exome regions (0.81 mutations per exome per year), owing to a large contribution from the transcription-coupled signature D (see below). Unlike in normal colon and small-intestine tissue, the contribution of age-related signature B is not conspicuous. Instead, signatures A and/or C are the major contributors to mutations in all cells, although no clear linearity was seen for signature A (Fig. 2e) . Conspicuously, SNVs in the colonies from high-risk individuals were Article reSeArcH disproportionally dominated by signature D. Except for signature A, the number of mutations in each signature linearly increased with age. However, unlike components of signature B and signature C-which exhibited an excellent linearity regardless of lifestyle ESCC risksignature D mutations in cells from high-risk individuals showed a large deviation from the linearity, providing further support for the link between signature D and alcohol consumption.
Driver mutations in PNE samples
Significantly mutated genes or drivers among 157 PNE samples were interrogated by globally gauging the recurrent involvement of nonsynonymous mutations across the entire genome 24 , and by locally assessing evidence for positive selection relying on dN/dS 7 . Both measures provided almost identical lists of driver genes. However, these drivers only partly (6 out of 10 genes) overlapped with lists calculated in a similar manner for the combined [16] [17] [18] [19] [20] ESCC cohort (n = 519) (Fig. 3a) , which suggests that there exist substantial differences in the major drivers between PNE and cancer. To further investigate this, we re-evaluated mutations in 24 genes that were significantly mutated in either PNE or cancer among the original 157 PNE samples, with higher sensitivity, using targeted deep sequencing (median 1,077×) (Fig. 3a) . Overall, mutations were found in all 24 drivers in PNE samples with distributions similar to those found in ESCC (Fig. 3a, b and Extended Data Fig. 6a ). However, mutation frequency of several genes substantially differed between PNE and cancer samples, suggesting the presence of discrete mechanisms of positive selection in PNE versus ESCC. TP53 was mutated in most cancer (414 out of 519, 79.8%) and dysplasia (11 out of 12, 91.7%) samples, but was much less so (48 out of 157, 30.6%) in PNE. In addition, NFE2L2, CDKN2A and FBXW7 were less frequently mutated in PNE than in cancer samples. By contrast, the most frequently mutated gene in PNE samples was NOTCH1 and other NOTCH family genes (104 out of 157, 66.2%), which forms a notable contrast to the disproportionately low frequency of NOTCH1 mutation in cancer samples (78 out of 519, 15.0%).
Another gene that was differentially mutated in cancer and PNE samples is PPM1D, which encodes a TP53-induced phosphatase, PPM1D. PPM1D negatively regulates p38 MAPK and inhibits phosphorylation of TP53, and thereby downregulates TP53-mediated transcription and apoptosis 25 . Although rarely seen in ESCC (0.58%), PPM1D mutations were found in a substantial fraction of PNE samples (12.7%). Other genes that were more frequently mutated in PNE than in ESCC include NOTCH2, ZFP36L2, FAT1, NOTCH3, CHEK2 and PAX9. The differential frequencies of driver mutations between cancer and PNE samples were largely recapitulated by targeted-capture sequencing of matched cancer and PNE samples from an additional 68 patients with ESCC (Extended Data Fig. 6b) .
Most of the PNE samples from high-risk individuals (62 out of 64, 97%) contained one or more driver mutations, as exemplified in the samples from a single oesophagus (UPN32) (Extended Data Fig. 2c, d ). By contrast, PNE samples from low-risk individuals-particularly 0.2-mm 2 samples from younger individuals-frequently lacked known driver mutations; the positivity of driver mutations was 74% (69 out of 93) of all samples from low-risk individuals. The effect of the age of the subject on the number of driver mutations and their clone size was evident (Extended Data Fig. 6c, d ). Lifestyle ESCC risk also affected the number of driver mutations, even after the effect of age was adjusted (Extended Data Fig. 6c , e, f). The effect of lifestyle risk on mutation frequency was most prominent for NOTCH1 mutations, followed by mutations in PPM1D, EP300, TP53 and NOTCH2 ( Fig. 3c and Extended Data Fig. 6f ). Lifestyle risk also affected maximum MCF, although the effect was less prominent for individual mutations (Extended Data Fig. 6d , g, h). Multiple mutations that affect the same gene-particularly those affecting NOTCH1 and TP53-were frequently detected in samples from high-risk individuals aged ≥50 years (45 out of 54) ( Fig. 3d ), but were not seen in samples from lowrisk younger (<50 years) individuals (0 out of 40).
Copy-number abnormalities in PNE
All but one cancer sample in our cohort displayed extensive CNAs. CNAs were also seen in all dysplastic tissues, but were less extensive than found in cancer samples (Extended Data Fig. 7a, b) . In PNE samples, CNAs were rare as a whole, but their frequency increased with age and was slightly enhanced by exposure to lifestyle ESCC risks (Extended Data Fig. 7c ). CNAs in PNE were largely confined to a small number of selected chromosomes, and are mostly explained by uniparental disomy of chromosome 9q (9q UPD) (49 out of 64 CNA-positive PNE samples, 77%) (Extended Data Fig. 7a, d ). 9q UPD was more frequent in PNE from elderly individuals-particularly those with lifestyle ESCC risks (Extended Data Fig. 7e ). In PNE, all 9q UPDs affected the NOTCH1 locus in common and were invariably accompanied by NOTCH1 mutations, which suggests that mutated NOTCH1 is the target of 9q UPD or loss of heterozygosity on chromosome 9q (9q LOH) (Extended Data Fig. 7d ). 9q LOH was more frequent in cancer and dysplasia samples (48 out of 57, 84%) than in PNE samples. However, in these cancer and dysplasia samples, 9q LOH was more frequently caused by deletion than UPD, and often extended to the 9p arm. Moreover, the majority of the cancer and dysplasia samples with 9q LOH (40 out of 57) lacked NOTCH1 mutations. These findings suggest the presence of targets of 9q LOH other than NOTCH1 (such as CDKN2A) (Extended Data Fig. 7d ). Other recurrent CNAs in PNE included gain of chromosome 3q (8.5%) and LOH of chromosome 17p (7.4%), of which the latter represents a major mechanism of bi-allelic inactivation of TP53 in ESCC as well as in other cancer types (Extended Data Fig. 7f, g ).
Structure and history of clones in PNE
To investigate clonal architecture in PNE, we performed a high-density collection of 0.2-mm 2 PNE samples (each containing about 10,000 cells; Extended Data Fig. 2g ) from 16 single-biopsy specimens with a median of 22 (range, 8-34) samples per biopsy, followed by WES or targeted-capture sequencing of the 24 ESCC or PNE drivers ( Fig. 4 and Extended Data Figs. 1c, 8, 9) . Analysis of densely collected micro-scale samples enabled us to decipher the spatial distribution and mutational composition of clones more precisely, compared with the analysis of solitary samples (Extended Data Fig. 9 ).
In the three specimens taken from low-risk individuals in their 20s ( Fig. 4b and Extended Data Figs. 8b-d, 9a, b), small numbers of mutations with small MCFs were shared by discrete sets of samples. The samples in each set carried much higher numbers of private mutations than of shared mutations and were observed over epithelial areas that were as large as 18.1 mm 2 , being spatially interrupted by other samples with which no mutations were mutually shared. These findings suggest that from early development to early adult life, multiple stem cells and their progenies in the rapidly enlarging oesophagus spread over a nearby region, become intermingled with each other, and-after adolescence-locally replenish the oesophageal epithelium in which they reside. Thus, the small number of mutations (median of 1 (range, 0-6), equivalent to 1.9 years (range 0-11.3 years)) that are acquired before spreading should be considered as representing somatic mosaicism rather than positive selection. Driver mutations were found in only a fraction of samples with small MCFs and rarely involved ≥2 samples ( Fig. 4b and Extended Data Fig. 9a, b) , which suggests that a limited number of driver-mutated clones expanded to the detectable size.
By contrast, PNE in elderly individuals had substantially different clonal architectures, as exemplified in five biopsies from three highrisk (UPN39, UPN134 and UPN135) and two low-risk (UPN55 and UPN59) individuals aged ≥70 years ( Fig. 4c and Extended Data 
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Figs. 8e, 9f, g). Shared mutations markedly increased in their number and MCF. Compared with mosaic mutations, they were more likely to be segregated into discrete sets of ≥2 samples (median of 3; range, 2-10), which were tightly clustered together and kept in close proximity to each other, occupying a relatively small region no larger than 12.8 mm 2 (median 2.87 mm 2 ; range, 0.79−12.8 mm 2 ) (Fig. 4a ). In the combined set of results from all 16 biopsies, the density of expanded driver-mutated clones increased with age and the trend was enhanced by exposure to lifestyle ESCC risk (Fig. 5a ). Although driver-mutated clones account for only ≤20% of all epithelial areas before 50 years of age, they increased in number and size with ageing; at the age of 70, they have replaced a substantial fraction of the entire oesophageal epithelium (Fig. 5b) . Elderly, high-risk individuals exhibited a higher mutation density (≥50 years old; 7.5-103.8 mutations per cm 2 ) and a larger size of TP53-mutated clones, as compared to younger, low-risk individuals (<50 years old; 0-18.3 mutations per cm 2 ) (Fig. 5c ). Clones that carried bi-allelic TP53 lesions were exclusively seen in biopsies from high-risk individuals. Consistent with the observation in solitary sampling, a higher NOTCH1 mutation density was observed in biopsies from elderly, high-risk individuals (35.1-173.1 mutations per cm 2 ) than younger, low-risk individuals (0-39.5 mutations per cm 2 ), particularly for bi-allelic mutations (Fig. 5c ). PPM1D mutations also tended to be more frequent in elderly, high-risk individuals.
Unbiased detection of mutations in densely collected micro-scale samples also enabled us to illustrate the complexity of evolutional history of expanded clones, which is inseparably linked to the geographic substructure of PNE (Fig. 6a and Extended Data Fig. 10) . In a representative PNE biopsy specimen, obtained from an 81-yearold high-risk individual, divergent clones that populated a small epithelial region (about 1.8 mm 2 ) originated from a single stem cell that had acquired a NOTCH1 mutation almost 80 years previously, when the subject was younger than about 1.9 years of age (Fig. 6a,  left) . Through a series of recursive positive selections over approximately 80 years, 4 additional driver mutations were fixed in the different subpopulations in varying combinations. In another example, clonal evolution was initiated by a stem cell in which a TP53 mutation occurred before the age of about 13.2 years (Fig. 6a, right) . Acquiring additional driver mutations in discrete evolutional branches, the TP53-mutated cell population derived from this stem cell persisted for over 50 years without evolving to cancer, and inhabited an approximately 6.6-mm 2 PNE region in the 70-year-old subject. In other clones, driver mutations were frequently acquired before 20 years of age (Extended Data Fig. 10) . Importantly, when evolutional patterns were compared between clones observed in high-(n = 17) and low-risk (n = 12) elderly individuals, substantial differences were observed; in high-risk subjects, 
. P value is given for significance between samples from low-risk and high-risk individual (one-sided Mann-Whitney U-test).
The number of independent TP53 (T) and NOTCH1 (N) mutations in each biopsy specimen is also depicted. ND, not determined. b, The fraction of total sampling area occupied by the indicated number of driver mutations is plotted for each biopsy specimen. c, Mutation density for each mutation (top) and fraction of total sampling area occupied by indicated mutations (bottom) are plotted for biopsy specimens from high-risk and low-risk individuals. The age and sex of the subject, and their exposure to lifestyle ESCC risks, are indicated in the bottom panels. * indicates WES. (Fig. 2) is also shown. Imputed clonal structures are depicted at the bottom, in which the estimated cellular prevalence of imputed mutational clusters (vertical axis) in each sample are shown as the distribution of posterior probabilities (width of the violin plots), calculated from the PyClone model. Colours correspond to those in the associated phylogenetic trees. b, Box plots of the number of evolutional branches, the maximum and total lengths of branches, and the total number of driver mutations between clones from high-risk (n = 17 clones) and low-risk (n = 12 clones) individuals, in which the median and first and third quartiles are indicated with whiskers that extend to the furthest value within 1.5× interquartile range. P values for significant differences are from two-sided Mann-Whitney U-test. c, Mutational signatures of mutations in early (<20 years old) versus late (>20 years old) branches are shown for clones in one low-risk and three high-risk individuals. evolutional trees are characterized by a significantly taller tree height, more branches, a longer total length of branches and a higher number of driver mutations (Fig. 6b and Extended Data Fig. 10 ), all of which combined suggest that lifestyle ESCC risks significantly accelerated clonal evolution. Compared with the mutations acquired in early life (<20 years old), mutations acquired in later life (>20 years old) exhibited an increased number of signature D mutations, which was not observed in low-risk individuals (Fig. 6c) . This suggests that, in adult life, lifestyle ESCC risks-most probably heavy drinking-contribute to the accumulation of mutations.
Discussion
Through an unbiased detection of somatic mutations in PNE from a large number of subjects, we demonstrated a comprehensive landscape of clonal expansion in PNE and revealed the ultrastructure of expanded clones and their evolutional history. The remodelling of the oesophageal epithelium by numerous driver-mutated clones is an inevitable consequence of normal ageing, leading to age-related clonal expansion in the oesophageal epithelium. Clones emerge multifocally in virtually all individuals as early as in early infancy. These clones increase their number and size over the years, and eventually remodel almost the entire oesophageal epithelium with thousands of sizable driver-mutated clones (about 9,000−15,000 clones per oesophagus). This can proceed even in the absence of heavy alcohol drinking and smoking, but-when presentthese lifestyle risks substantially accelerate this remodelling process.
Despite a large number of driver-mutated clones in every elderly individual, an estimated lifetime incidence of ESCC remains between only about 1 in 45 or 1 in 228 and those who develop ESCC are in large part limited to heavy drinkers and smokers 26 , suggesting a critical role of these lifestyle risks in ESCC development. Given the strong effect of lifestyle ESCC risk on the number and type of driver mutations that are positively selected in age-related clonal expansion, of particular interest is a previous study that shows a critical role of mutagens in tumorigenesis in NOTCH1-deficient skin, in which treatment with a mutagen (7,12-dimethylbenz[a]anthracene) was essential for accelerated tumour development in Notch1-deleted mouse skin 27 . Importantly, in this model, the mutagen-induced tumours developed even from residual Notch1-intact cells, which suggests the presence of non-cell autonomous effects of NOTCH1-deficient cells. This raises the possibility that field effects for ESCC carcinogenesis could be explained by the cooperation between age-related clonal expansion of NOTCH1-mutated clones and exposure to lifestyle ESCC risks, in which consumption of large amounts of alcohol and tobacco-well-known mutagenic agents-accelerates carcinogenesis in the tumour-prone oesophageal milieu created by the expansion of multiple NOTCH1-mutated clones.
Finally, our current observations raise the question of what the essential difference is between clones in PNE and cancer. Our knowledge is still limited regarding the mechanism of clonal evolution in normal tissues, and the way in which this differs from cancer evolution-these are important issues that remain to be addressed in understanding cancer and developing strategies for early detection, intervention and even prevention of ESCC in high-risk patients.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Subjects and materials. We enrolled a total of 139 patients who underwent surgery and/or therapeutic or diagnostic endoscopy for upper gastrointestinal symptoms at Kyoto University Hospital and other participating institutes. Among these, 95 had ESCC (n = 93) or high-grade oesophageal dysplasia (n = 2), and the remaining 44 had no oesophageal lesions and are considered to be healthy individuals. Informed consent was obtained from all participants. Characteristics of these patients and healthy individuals are summarized in Supplementary Table 1. A history of heavy alcohol drinking (≥396 g alcohol per week) or tobacco smoking (≥30 pack-years) was reported in 95 individuals, who were considered to have positive lifestyle ESCC risks 10, 13 (high-risk individuals). None of the patients included had received prior chemoradiotherapy. This study comprises the following 4 sequencing experiments (experiments 1-4) (Extended Data Fig. 1 and Supplementary Tables 1 and 2 ). Experiment 1 involved WES of solitary PNE and cancer samples, including those obtained by multi-regional sampling (189 ESCC, dysplasia or PNE samples from 62 subjects and 27 ESCC or PNE samples from a surgical specimen), followed by targeted deep re-sequencing of 24 driver genes for the PNE samples. Experiment 2 involved whole-genome sequencing (WGS) of single-cell-derived colonies (13 samples from 7 subjects). Experiment 3 involved the deep sequencing of 24 driver genes in cryo-archived samples of matched PNE and cancer (136 samples from 68 patients). Experiment 4 involved whole-exome or targeted panel sequencing of densely collected samples (16 biopsies from 14 subjects). In experiments 2 and 4, samples were obtained from overlapped subjects across the different experiments. This study was approved by the ethical committee at Kyoto University.
Biomaterials, including oesophageal tissues and peripheral blood, were newly collected from 71 individuals using endoscopic biopsy or stereoscope-guided sampling from a surgical specimen, according to procedures approved by the Internal Review Board at Kyoto University (G0645). For the remaining 68 patients, a cryo-preserved oesophageal biopsy with paired matched blood was provided from the Kyoto University Hospital Cancer Biobank (no. 1056). Endoscopic biopsies from multiple sites were performed in 17 individuals with a median of 5 biopsies per subject (range, 2−8) for experiments 1, 2 and 4. All subjects and samples were anonymized with unique identifiers before analysis. All the specimens obtained from patients with cancer or dysplasia, excluding cryo-preserved samples, were reviewed independently by two expert pathologists (Y.T. and S. Minamiguchi) at the Department of Diagnostic Pathology (Kyoto University) blinded to clinical information, to confirm histology based on the WHO Classification of Tumours of the Digestive System (4th edition) 28 . Accordingly, all the samples were categorized into one of four pathological groups; PNE, low-grade dysplasia, high-grade dysplasia and cancer.
For sequencing analysis of oesophageal tissues, we prepared a total of 559 samples from the newly obtained biopsy specimens under dissection microscope. Among these, 27 (25 PNE and 2 cancer samples) were from the surgically resected oesophagus of a 58-year-old high-risk patient with ESCC with a long history of heavy smoking (UPN32). The remaining 532 samples were prepared from 166 endoscopy biopsies, using razor (for 4-mm 2 samples; n = 118) or disposable biopsy punches BP-10F (for 0.8-mm 2 samples; n = 31) or BP-A05F (for 0.2-mm 2 samples; n = 383) (Kai Industries); these comprised 157 PNE, 12 dysplasia and 20 cancer samples for experiment 1, and 13 and 341 PNE samples for experiments 2 and 4, respectively (Extended Data Fig. 1 ). To enhance the sensitivity of mutation detection, submucosal layers were removed from each biopsy specimen before DNA extraction (Extended Data Fig. 2e) , except for the samples from surgically obtained specimens and archived frozen specimens. Peripheral blood samples were collected from all cases and used as germline controls. In particular, 16 biopsy specimens from 14 individuals were subjected to high-density sampling, through which a median of 22 (range, 8-34) samples were collected from a single biopsy with a uniform sampling size of 0.2 mm 2 (Supplementary Table 3 ). These samples-together with archived samples of paired PNE and cancer, and matched peripheral blood-from 68 patients with ESCC (n = 204), were subjected to extraction of genomic DNA with the DNeasy Tissue Kit (Qiagen) or QIAamp DNA Micro Kit (Qiagen), according to the manufacturer's protocols. Sample information is summarized in Supplementary Table 2 . External datasets. WES data (bam files) of paired tumour and germline control samples from patients with ESCC (n = 90) and other cancers (n = 8,808) were downloaded from the TCGA Data Portal (https://portal.gdc.cancer.gov/). WES data from a Japanese cohort of 142 patients with ESCC (Japan cohort) have previously been published 16 . The clinical data of these patients are summarized in Supplementary Table 1 . These bam files from the TCGA and the Japan cohorts were converted to fastq format using biobambam (https://github.com/gt1/biobambam) and processed with the same pipeline for mutation calling as applied to the current cohort (see below). Mutation lists of 272 ESCC samples were available from the publications of an additional three WES or WGS studies of ESCC [18] [19] [20] . Whole-exome sequencing. WES libraries were generated using SureSelect Human All Exon v.5 (Agilent Technologies), followed by sequencing of enriched exon fragments on HiSeq 2500 or NovaSeq 6000 (Illumina) with 100-150-bp paired-end mode, as previously described 29 . Depending on the purpose of experiments, the target depth was 150× (experiments 1 and 4)-the actual coverage was 185× (54×-425×) and 148× (47×-511×) on average, for experiments 1 and 4, respectively. The mean coverage in blood samples from 78 individuals was 144× (89×-233×). Mutation calling was performed using Genomon2 pipeline (https://genomon.readthedocs.io/ja/latest/) (Supplementary Methods 1), as previously described 30 . In brief, sequencing reads were aligned to the human genome reference (hg19) using Burrows-Wheeler Aligner, version 0.7.10, with default parameter settings. PCR duplicates were eliminated using Picard-tools version 1.39 (http://picard.sourceforge.net/). Somatic mutations were detected by eliminating polymorphisms and sequencing errors. To achieve this, Genomon2 first discards any low-quality, unreliable reads and variants, which are defined by the following criteria: (i) mapping quality < 30; (ii) base call quality < 15; and (iii) reads with ≥5 SNVs or indels. After further excluding variants that are not supported by a sufficient number of reads (total reads ≥ 10 and variant reads ≥ 3), variant allele frequencies (VAFs) ≥ 0.05 (for tissue sample) and ≤ 0.02 (for normal control), and strand ratio ≠ 0 or 1, the remaining variants are interrogated for evidence that they are observed at significantly higher VAFs than expected for errors (P ≤ 10
), for which significance is evaluated by EBCall algorithm 31 on the basis of an empirical VAF distribution, as determined using WES data of non-paired peripheral blood samples from the same sequencing run (n = 15-20). Putative germline variants are also excluded by comparing VAFs with matched control using the Fisher's test (≤10
, which also eliminates remaining additional sequencing errors. All variants within repetitive sequences were excluded to obtain a higher true-positive rate at the expense of sensitivity. In total, 8,056 candidate somatic mutations were called by Genomon2 pipeline.
Some modifications were made to the original pipeline. Mutations clustered within a short bp length (150 bp), as well as other mutations found across multiple samples, were subjected to visual inspection on the Integrative Genomics Viewer 33 , to further eliminate sequencing errors. Finally, we rescued mutations in driver genes-which were excluded by the stringent filters in the original mutation calling-by applying less stringent filters, with EBCall P value ≤ 10 −3 and Fisher's P value ≤ 10 −0.5 . For samples from the high-density collection (experiment 4), each of the mutations detected in a specimen was exhaustively interrogated in all the remaining samples; if a variant detected in one or more samples by EBCall was also present (VAF ≥ 0.05) in another sample within the biopsy specimen, the variant was considered to be true-positive (because it has a high prior probability for true positivity in the specimen). Validation of detected mutations. Validation of mutations detected by WES and WGS was performed using PCR-based deep (>500×) sequencing as previously described 29 , in which 622 SNVs and indels from WES and 94 SNVs and indels from WGS were selected and evaluated. A mutation was considered to be validated when (1) the sequencing depth was ≥500 in both test and germline control samples, (2) the VAF in the test sample was 5 times larger than that in the corresponding germline control sample, and (3) the VAF in the test sample was large enough (≥0.01) to be captured by the lower threshold in WES (0.05) 32 . The overall validation rate was 95.7% for WES (544/569 SNVs and 51/53 indels) and 94.7% for WGS (86/89 SNVs and 3/5 indels). The results of validation sequencing were summarized in Supplementary Table 4 . Detection of significantly mutated genes. Significantly mutated genes (driver genes) were detected by globally evaluating the number of nonsynonymous mutations with correction for gene size and local mutation rate using MutSigCV 24 with default settings. Driver genes were also investigated using dN/dS, which was calculated for all recurrently mutated genes-as well for all mutations detected by WES-using dNdScv 7 (https://github.com/im3sanger/dndscv). After independently applying each of these two packages to the mutations in 519 ESCC and 157 PNE samples, 24 genes that were found to be significantly mutated by either MutSigCV or dNdScv analysis (q < 0.05), and found in ≥2% of PNE or ESCC cohorts, were considered as drivers (Supplementary Tables 5, 6 and 7) . Targeted deep sequencing of driver genes in experiments 1, 3 and 4. Targeted deep sequencing was performed according to the manufacturer's protocols, using a custom bait library (xGen Predesigned Gene Capture Pools; IDT) that was designed to capture all 24 driver genes (Supplementary Table 7 ). Corresponding germline DNA from peripheral blood was also analysed, unless this DNA had been analysed by WES. After hybridization capture, the enriched DNA fragments were analysed on HiSeq 2500 or NextSeq 500, as previously described 29 . Except for paired cancer and PNE samples, all DNA samples were whole-genome-amplified before sequencing, using REPLI-g Mini Kit (Qiagen). Mutation calling in targeted capture was almost the same as that in WES, except that an EBCall P value < 10 −4 and a Fisher's P value < 10 −1 were used. Details of samples analysed with targeted deep sequencing are summarized in Supplementary Tables 1, 2 and 8 . Analysis of CNAs. CNAs were investigated using single nucleotide polymorphism (SNP) array and/or sequencing data (Supplementary Tables 1, 2 ). SNP array analysis was performed for paired cancer and non-cancer tissue samples, using GeneChip Human Mapping 250K NspI (Affymetrix) according to the manufacturer's instructions. All the SNP array data were uniformly analysed for CNAs using CNAG 34, 35 . For other samples (Supplementary Table 7 ), CNAs were evaluated on the basis of sequencing data using our in-house pipeline CNACS 36 . In particular, the bait-library for targeted-capture sequencing was designed to capture 1,760 SNP sites for the measurement of genomic copy numbers, in addition to capturing 24 ESCC or PNE drivers. Significant focal CNAs (q < 0.25) were detected using GISTIC 2.0 37 with a default setting based on the copy-number data obtained above (Supplementary Table 9 ). Estimation of MCFs. Precise estimation of the cell fraction with a somatic mutation (the MCF) can be complicated when the mutation involves a gene located on a chromosomal segment that shows an abnormal copy number or an allelic imbalance 38 . Fortunately, most PNE samples had no copy-number abnormality and no allelic imbalance existed at the mutated locus. Thus, for most mutations in PNE samples (5,850 out of 6,216), MCF is simply estimated from the observed variant allele frequency (VAF) as follows: MCF = 2 × VAF (for autosomes and the X chromosome in females), or MCF = VAF (for the X chromosome in males).
By contrast, when the mutated locus did show an abnormal copy number or an allelic imbalance, the estimation of MCF depends on several factors that cannot be inferred in a deterministic way, particularly in cases in which a sample contains multiple clones with different compositions of mutant alleles. However, the vast majority of CNAs in PNE samples were 9q UPD and 17p UPD or deletion targeting mutated NOTCH1 (n = 123) and TP53 (n = 27), respectively, in which mutations are thought to precede respective CNAs in most cases. Thus, for TP53 and NOTCH1 mutations in 17p LOH-positive and 9q UPD-positive sampleswhich accounted for 2.4% (150 out of 6,216) of all detected mutations-MCF was calculated according to the following formula: MCF = 2 × VAF − per cent UPD/100 (for UPD) and MCF = VAF × (2 − per cent deletion/100) (for deletion), where per cent UPD and per cent deletion denote the estimated fraction (in per cent) of the respective abnormality. For other mutations associated with CNAswhich accounted only for 3.3% (n = 208) of mutations in PNE, and of which only 6 were mutations that affected drivers-MCF was also estimated according to the above formula (for mutations associated with deletion or UPD) or the mutations were excluded from the analysis of clone size (for mutations associated with copy number gain). MCFs were also calculated for mutations in dysplasia and ESCC samples in a similar manner. All the analyses in which the maximum values of MCF (maximum MCF) were evaluated were performed exclusively on those samples carrying at least one mutation. Analysis of mutational signature. Mutational signatures of 54,121 SNVs in 157 PNE, 12 dysplasia and 519 cancer samples were extracted using the R package pmsignature 39 . For multiple samples that were collected from the same cancer specimen, the sample that was collected at or nearest to the centre of specimen was subjected to the analysis. For comparison with the COSMIC signatures, mutations were allocated to 30 COSMIC mutational patterns using R package MutationalPatterns 40 . The frequency of each signature was compared between PNE, dysplasia and cancer samples. The effects of the age of the subject and lifestyle ESCC risks on the number of mutations assigned to each signature were evaluated as described in 'Statistical analysis' . Genotyping of the two SNPs in ALDH2 (rs671) and ADH1B (rs1229984) was determined for 8,898 TCGA samples on the basis of the WES data of corresponding normal controls, in which samples were classified as homozygote if VAFs for either A or B allele exceeded 0.8, or otherwise as heterozygote. VAFs of each polymorphic allele were calculated by performing local realignment around SNPs using GenomonMutationFilter realignment (https://github. com/Genomon-Project/GenomonMutationFilter) with the default setting. Samples with less than 20 reads were excluded from the analysis. Frequency of mutations allocated to signature C in ESCC samples was compared between samples with or without alcohol drinking and/or smoking. For TCGA pan-cancer cohort, we compared the number of mutations allocated to COSMIC signature 16 between ALDH2 genotypes in each cancer type. WGS of single-colony-derived sample. To measure the mutation rate at the singlecell level, and its age-dependence, we isolated 13 single PNE cells from 5 low-risk healthy individuals and 2 high-risk patients with ESCC by limiting dilution after 3-5 days of primary culture from biopsy specimens. Isolated single cells were further cultured with KSFM supplemented with 50 ng/ml BPE and 1 ng/ml EGF for 2-3 weeks, followed by DNA extraction, in which the median recovery was 92 ng (range, 40-399 ng) per single-cell culture. Library preparation for WGS was performed using KAPA Hyper Prep Kit, followed by sequencing with 63× depth using NovaSeq 6000 with matched blood DNA (35×). The Genomon2 pipeline was used for mutation calling with the same parameters as used for WES, except that the EBCall P value, the Fisher's P value and VAFs were ≤10 −6 , ≤10 −1 and ≥0.25, respectively. Detected mutations were allocated to signatures A-D, which were identified in PNE and ESCC samples, using MutationalPatterns 40 . Detection of clones in high-density sampling. To investigate the clonal structure found in a set of densely collected samples, we first grouped all the mutations detected in these samples into those found in multiple samples ('shared mutations') and those found in only a single sample ('private mutations'). The former are further grouped into discrete sets of mutations (S 1 , S 2 , S 3 , …, S N ), each of which comprises those mutations mutually co-segregated with each other into a set of samples or contains only a single mutation that was not co-segregated with any other mutations. When a given set of mutations, S i , does not co-occur with any other sets of mutations, S i by itself defines a unique clone. Even when S i co-occurs with another set, for example, S j , in one or more samples, each of S i and S j defines a discrete clone, in the case where some samples contain S i alone, while others contain S j alone. Otherwise, there exists at least one sample that contains only one of the two sets of mutations. In this case, if the sum of the maximum MCF in S i and S j exceeds 1.0 in a sample, the presence of two discrete clones can be predicted: the clone harbouring both sets of mutations and the other one carrying only one of the two showing the larger maximum MCF (pigeonhole principle). If this principle does not hold, it is impossible to determine whether two sets of mutations define two discrete clones or whether one is included by the other one; in this case we adopted only one of the two-the one showing a larger maximum MCF-while excluding the other from the further analysis of clonal structures. Finally, the presence of a discrete clone was predicted from private mutations when a sample contained only private mutations, or when the maximum MCF among private mutations exceeded those of shared mutations.To reconstruct a hierarchical tree, we first generated discrete sets of samples so that each set shares at least one mutation that is not shared by the remaining samples. For each set of samples, clonal composition was investigated on the basis of the beta binomial emission model implemented in PyClone version 0.13.0 41 , through which a set of clones with a discrete set of mutations (mutational clusters) were imputed together with their estimated clone size (cellular prevalence). For each mutational cluster, cellular prevalence in each sample was used to reconstruct a hierarchical tree in the same manner described above.
After the reconstruction of hierarchical trees, the number of branches, the maximum and total lengths of branches, and the total number of driver mutations were calculated for each clone in elderly high-risk and elderly low-risk subjects (Supplementary Table 10 ). Mutations that belonged to each branch of clones were divided into early (acquired at <20 years old) and later mutations (acquired at >20 years old), according to the mutation rate in exon region (0.531 and 0.8098 mutation per year for low-risk and high-risk cases, respectively) that was estimated from WGS of single-cell-derived colonies. Early and late mutations were independently allocated to signatures A-D (see above), using MutationalPatterns. Criteria for bi-allelic mutations. Bi-allelic mutations were thought to be present, if (1) the sum of the MCFs of multiple mutations that affected a same gene exceeded 1.0, or (2) the locus of the mutated gene showed LOH. Measurement of the areas of mutant clones by high-density sampling. In high-density, micro-scale (0.2 mm 2 ) sampling, many mutations were observed in multiple samples-particularly in elderly and high-risk cases. The expansion of each mutant clone in high-density sampling was evaluated in terms of (1) the sum of MCFs × sampling area (0.2 mm 2 ) for each of the affected samples and (2) the size of the minimum circle that encompassed all the mutation-positive samples ('minimum circle'). The size of the minimum circle was calculated for all mutations shared by ≥2 samples, in which each sample was considered to be a 0.2-mm 2 circle located at the coordinate recorded during micro-scale biopsy (Fig. 4a) . In analysis of density of clones with driver mutations in high-density sampling, the minimum circle that encompassed all the samples was used as the area of each specimen (Fig. 5a) . Estimation of mean cell density in PNE. The amount of DNA in a human somatic cell can be calculated using the mean recovery of DNA from punch biopsy. To minimize the effect of the lower recovery of DNA that is anticipated for small samples, the mean recovery from 4-mm 2 samples (1,223 ng per sample) (Extended Data Fig. 2g ) was used for the calculation, assuming a typical recovery of ~90%. Assuming ~6.6 pg DNA per single diploid cell, we estimated the mean cell density of ~51,500 cells per mm 2 or 10,300 cells per 0.2 mm 2 . Statistical analysis. Statistical analyses were performed using R, version 3.5.1. All P values were calculated by two-sided analysis unless otherwise specified. The Fisher's exact test or Mann-Whitney U-test was used for group comparisons. Confidence intervals of frequency of positive samples were estimated using binomial test. Multiple testing was corrected based on Benjamini-Hochberg q values. The independent effects of lifestyle ESCC risk on the enrichment of mutations in high-risk individuals were tested in driver genes that were mutated in 5% or more of the PNE samples, by evaluating the improvement in a logistic regression model that incorporated both age and lifestyle risk versus a model that incorporated age Article reSeArcH alone, using an ANOVA. The linearity of the number of mutations and MCFs with age was evaluated on the basis of the Pearson's correlation coefficient in a linear regression model that assumed zero intercept for samples from low-risk individuals but not for samples from high-risk individuals, because exposure to risks for ESCC usually begins after adolescence. The significance of the correlation of age with these variables in low-risk samples was tested using an F test. The significance of the effect of lifestyle risks on the number of mutations, MCFs and frequencies of samples with a driver mutation was tested using the one-side Welch's t-test under the null hypothesis that residuals in the regression model for high-risk samples follow the same distribution as those for low-risk samples. Observations in the different sample sizes were combined using a random-effects model meta-analysis with R package metaphor 42 , in which the mean difference of residuals between high-risk and low-risk samples were standardized across different sample sizes without assuming equal variance and tested for significance. Correlation coefficients for age in the different sample sizes among low-risk samples were combined with Fisher's r-to-z transformation. Code availability. CNACS is a UNIX-based program for sequencing-based copy-number analysis, which is available from http://plaza.umin.ac.jp/kyoto_ tumorpatho/CNACS.html. A custom R script for the random-effects model meta-analysis is available in Supplementary Methods 2. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper. 
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